Our meta-analysis included four RCTs and 423 patients with liver cirrhosis, and the results confirmed that compared to placebo for patients with liver cirrhosis, emricasan treatment showed no improvement in MELD, INR, total bilirubin or serum albumin. The gene discussed is ALB; the disease is cirrhosis of liver.